Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Gregory Tino

Critical Care Medicine Philadelphia, PA Medical Doctor

NPI 1851323851 CMS profile 729372

3400 Spruce Street, Philadelphia, PA 19104

Open in the dashboard

General payments

$9,345

7 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Gregory Tino of Philadelphia, PA is reported in the CMS Open Payments database as having received $9,345 across 7 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $2,440 1
2020 General $2,140 1
2019 General $4,766 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Tino
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Gregory Tino were reported at $0. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Gregory Tino Critical Care Medicine median Middle half National median
2019 $4,766 $149 $51–$535 $163
2020 $2,140 $110 $30–$325 $114
2021 $2,440 $125 $34–$403 $132
2022 $0 $157 $49–$582 $149
2023 $0 $162 $56–$621 $160
2024 $0 $168 $53–$634 $164
2025 $0 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. AstraZeneca UK Limited $4,474 2 payments
  2. Insmed, Inc. $2,672 3 payments
  3. Cipla USA Inc. $2,200 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Consulting Fee $9,114 5 payments
  2. Food and Beverage $232 2 payments
Products named General payments · program years 2019–2021
  1. FASENRA $4,474 2 payments
  2. 4 $2,200 2 payments
  3. Arikayce $142 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

646

Median for Pulmonary Disease: 936

Drug cost

$875,210

Median for Pulmonary Disease: $487,987

Branded share of claims

70%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 38 $509,984
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 92 $122,768
Pirfenidone Generic 14 $107,296
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 90 $61,742
Breo Ellipta Fluticasone/Vilanterol Brand 48 $22,264
Incruse Ellipta Umeclidinium Bromide Brand 47 $22,240
Colistimethate Colistin (Colistimethate Na) Brand 25 $20,632
Albuterol Sulfate Hfa Albuterol Sulfate Brand 61 $2,577
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 15 $1,623
Mycophenolate Mofetil Generic 11 $1,518

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$33,999

Medicare's payments for the services billed

Medicare patients

176

Average age 76

Services billed

383

121 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
COPD 64%
Arthritis 48%
Ischemic heart disease 39%
Osteoporosis 32%
Chronic kidney disease 29%
Heart failure 26%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

7 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record